The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications—2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum

Author:

Byndloss Mariana12ORCID,Devkota Suzanne3ORCID,Duca Frank4ORCID,Niess Jan Hendrik56ORCID,Nieuwdorp Max78ORCID,Orho-Melander Marju9ORCID,Sanz Yolanda10ORCID,Tremaroli Valentina11ORCID,Zhao Liping12ORCID

Affiliation:

1. 1Vanderbilt University Medical Center, Nashville, TN

2. 2Howard Hughes Medical Institute, Vanderbilt University Medical Center, Nashville, TN

3. 3Human Microbiome Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA

4. 4University of Arizona, Tucson, AZ

5. 5Department of Biomedicine, University of Basel, Basel, Switzerland

6. 6Department of Gastroenterology and Hepatology, University Digestive Healthcare Center, Clarunis, Basel, Switzerland

7. 7Department of Internal and Vascular Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands

8. 8Amsterdam Diabeter Center, Amsterdam University Medical Centers, Amsterdam, the Netherlands

9. 9Department of Clinical Sciences in Malmö, Lund University Diabetes Centre, Lund University, Malmö, Sweden

10. 10Institute of Agrochemistry and Food Technology, Spanish National Research Council (IATA-CSIC), Valencia, Spain

11. 11Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

12. 12Department of Biochemistry and Microbiology, School of Environmental and Biological Sciences, Rutgers University, New Brunswick, NJ

Abstract

This article summarizes the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organized by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: 1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g., genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomization in humans; 2) the highly individualized nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; 3) because single–time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and 4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal.

Funder

ZONMW-VICI

European Union’s Innovative Medicine Initiative

Swiss National Science Foundation

Severo Ochoa Center of Excellence

Novo Nordisk Foundation

DFN-DON

National Institute of Diabetes and Digestive and Kidney Diseases

Spanish Ministry of Science, Innovation and Universities MICIU/AEI

Publisher

American Diabetes Association

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3